Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for vision restoration, today announced it has been awarded an $8 million grant from the California Institute for ...

Blocking the PROX1 protein allowed KAIST researchers to regenerate damaged retinas and restore vision in mice. Vision is one ...

For some creatures, a lost body part is not necessarily a permanent affair. Salamanders can regrow limbs and zebrafish can ...

ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there ...

The FDA granted regenerative medicine advanced therapy designation to ATSN-201, a gene therapy candidate for the treatment of ...

Four young children have gained life-changing improvements in sight following treatment with a pioneering new genetic ...

vitrectomy in retinal detachment surgery. SEVILLE, Spain — Gene therapy is an area of intensive research and development in the retina space, with promising prospects and significant challenges.

ATSN-201, a best-in-class gene therapy product candidate, leverages AAV.SPR, the company's novel spreading capsid, to achieve therapeutic levels of gene expression in photoreceptors of the central ...

New studies in rats suggest the drug reserpine, approved in 1955 for high blood pressure, might treat the blinding disease retinitis pigmentosa.